171 related articles for article (PubMed ID: 31216214)
1. Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L
Expert Opin Ther Pat; 2019 Jul; 29(7):481-485. PubMed ID: 31216214
[No Abstract] [Full Text] [Related]
2. Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Rosas-Murrieta NH; Millán-Pérez Peña L
Expert Opin Ther Pat; 2020 Feb; 30(2):83-86. PubMed ID: 31874056
[No Abstract] [Full Text] [Related]
3. Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1.
Perez-Santos M; Anaya-Ruiz M; Cebada J; Herrera-Camacho I
Expert Opin Ther Pat; 2019 May; 29(5):311-314. PubMed ID: 30990738
[TBL] [Abstract][Full Text] [Related]
4. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L; Rosas-Murrieta NH
Expert Opin Ther Pat; 2019 Dec; 29(12):921-924. PubMed ID: 31627712
[No Abstract] [Full Text] [Related]
5. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.
Herrera-Camacho I; Anaya-Ruiz M; Perez-Santos M; Millán-Pérez Peña L; Bandala C; Landeta G
Expert Opin Ther Pat; 2019 Aug; 29(8):587-593. PubMed ID: 31241380
[No Abstract] [Full Text] [Related]
6. OX40 agonists for cancer treatment: a patent review.
Cebada J; Perez-Santos M; Bandala C; Lara-Padilla E; Herrera-Camacho I; Rosas-Murrieta NH; Millán-Pérez Peña L; Monjaraz E; Flores A; Anaya-Ruiz M
Expert Opin Ther Pat; 2021 Jan; 31(1):81-90. PubMed ID: 32945223
[TBL] [Abstract][Full Text] [Related]
7. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J
Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045
[TBL] [Abstract][Full Text] [Related]
8. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652.
Perez-Santos M; Guerrero-González T; Gómez-Conde E; Cebada J; Flores A; Villa-Ruano N
Expert Opin Ther Pat; 2020 Mar; 30(3):159-162. PubMed ID: 31944149
[No Abstract] [Full Text] [Related]
10. Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232.
Villa-Ruano N; Guerrero-González T; Gómez-Conde E; Perez-Santos M
Expert Opin Ther Pat; 2020 Oct; 30(10):723-727. PubMed ID: 32787475
[TBL] [Abstract][Full Text] [Related]
11. Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
[TBL] [Abstract][Full Text] [Related]
12. Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.
Polesso F; Weinberg AD; Moran AE
Cancer Immunol Res; 2019 Feb; 7(2):269-281. PubMed ID: 30563828
[TBL] [Abstract][Full Text] [Related]
13. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
Chen M; Ouyang H; Zhou S; Li J; Ye Y
Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
[TBL] [Abstract][Full Text] [Related]
14. LAG-3 antagonists by cancer treatment: a patent review.
Perez-Santos M; Anaya-Ruiz M; Cebada J; Bandala C; Landeta G; Martínez-Morales P; Villa-Ruano N
Expert Opin Ther Pat; 2019 Aug; 29(8):643-651. PubMed ID: 31291131
[No Abstract] [Full Text] [Related]
15. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
16. Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients' response to cancer immunotherapy.
Omar HA; Tolba MF
Crit Rev Oncol Hematol; 2019 Mar; 135():21-29. PubMed ID: 30819443
[TBL] [Abstract][Full Text] [Related]
17. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
18. Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer.
Ingles Garces AH; Au L; Mason R; Thomas J; Larkin J
Expert Opin Investig Drugs; 2019 Aug; 28(8):695-708. PubMed ID: 31359805
[No Abstract] [Full Text] [Related]
19. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
